Michele Del Vecchio

Fondazione IRCCS Istituto Nazionale dei Tumori — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

49h-index12.5kcitations330works8.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(119), Cancer Immunotherapy and Biomarkers(117), CAR-T cell therapy research(108), Cutaneous Melanoma Detection and Management(69), Immunotherapy and Immune Responses(60)

Publications324 total

High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors
Journal of Translational Medicine·2025Open Access
Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
2025Open Access
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
New England Journal of Medicine·2025· 8 cited
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial
Nature Medicine·2025· 2 citedOpen Access
1621P First-line pembrolizumab alone or with investigational agents for advanced melanoma: Updated results from the phase I/II KEYMAKER-U02 substudy 02B
Annals of Oncology·2025
1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma
Annals of Oncology·2025· 1 citedOpen Access
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
Journal for ImmunoTherapy of Cancer·2025· 3 citedOpen Access
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
European Journal of Cancer·2025· 1 citedOpen Access
Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.
Journal of Clinical Oncology·2025· 4 cited
Tebentafusp in metastatic uveal melanoma patients: Results of the Italian expanded access program.
Journal of Clinical Oncology·2025· 1 cited
Melanoma in children and adolescents: Distinct biology, evolving therapies, and unmet needs
Tumori Journal·2025
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study
European Journal of Cancer·2025· 8 cited
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
European Journal of Cancer·2025· 5 citedOpen Access
Dabrafenib and Trametinib for the Treatment of Pediatric and Adolescent Melanoma: Single Center Experience Data From Italian Compassionate Use
Pediatric Blood & Cancer·2025· 4 citedOpen Access
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Annals of Surgical Oncology·2025· 3 cited
Recent advances in the prevention and treatment of dental erosion: a narrative review.
Oral & Implantology·2024Open Access
Emphasizing HPV infection and the molecular processes in oral cancer development
Oral & Implantology·2024Open Access
Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP–MADAM (Maximing ADjuvAnt MAP): Interim Analysis
Cancers·2024Open Access
Abstract B027: Combining total cell-free DNA (cfDNA) and circulating tumor (ctDNA) to enhance the clinical sensitivity of ddPCR assays to detect minimal residual disease (MRD) in stage IIIB/C/IV melanoma patients on adjuvant immunotherapy in CheckMate 238
Clinical Cancer Research·2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma
NEJM Evidence·2024· 7 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

Paolo A. Ascierto(27), Paola Queirolo(23), Vanna Chiarion‐Sileni(22), Mario Mandalà(18), Michele Maio(16), Ana Arance(12), Piotr Rutkowski(11), Lorenza Di Guardo(11), Georgina V. Long(10), Pier Francesco Ferrucci(10), Helen Gogas(9), Jean‐Jacques Grob(9), Anna Maria Di Giacomo(9), Jacopo Pigozzo(9), Ester Simeone(8), Francesco Spagnolo(8), Michele Guida(8), Jeffrey S. Weber(7), James Larkin(7), Caroline Robert(7)